New study shows lupus drug may reduce Long-Term organ damage
NCT ID NCT06485674
First seen Apr 23, 2026 · Last updated May 14, 2026 · Updated 4 times
Summary
This study looked at whether the drug anifrolumab, when added to standard treatment, can prevent long-term organ damage in adults with active lupus. Researchers compared data from 561 patients who took anifrolumab in earlier trials to similar patients receiving only standard care. The goal was to see if anifrolumab helps reduce damage to organs like the kidneys or heart over about 4 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG-TERM ORGAN DAMAGE IN ADULT PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Toronto, Ontario, M5G 1L7, Canada
Conditions
Explore the condition pages connected to this study.